Last reviewed · How we verify
Discontinuation antipsychotic treatment
This is a clinical trial protocol studying the effects of discontinuing antipsychotic medication in patients currently treated with antipsychotics.
This is a clinical trial protocol studying the effects of discontinuing antipsychotic medication in patients currently treated with antipsychotics. Used for Evaluation of antipsychotic discontinuation outcomes in schizophrenia or related psychotic disorders, Assessment of relapse risk and symptom recurrence following antipsychotic withdrawal.
At a glance
| Generic name | Discontinuation antipsychotic treatment |
|---|---|
| Also known as | Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol |
| Sponsor | Fundación Pública Andaluza Progreso y Salud |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This is not a drug itself, but rather a clinical study design (Phase 3) investigating what happens when antipsychotic treatment is stopped in patients. The trial likely examines relapse rates, symptom recurrence, safety, and outcomes associated with antipsychotic discontinuation versus continuation in conditions like schizophrenia or bipolar disorder.
Approved indications
- Evaluation of antipsychotic discontinuation outcomes in schizophrenia or related psychotic disorders
- Assessment of relapse risk and symptom recurrence following antipsychotic withdrawal
Common side effects
- Psychotic relapse or symptom recurrence
- Withdrawal-emergent dyskinesia
- Rebound psychosis
Key clinical trials
- Caplyta in Borderline Personality Disorder (PHASE2)
- Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
- Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) (PHASE3)
- Predictors of Functional Remission in Discharged Patients With Schizophrenia After Long-term Drug Discontinuation
- Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs (PHASE4)
- The Efficacy of Probiotics for the Treatment of Alcohol Use Disorder Among Adult Males (NA)
- Research Into Antipsychotic Discontinuation and Reduction Trial (PHASE4)
- Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: